Andrea E. Formella

Pseudobulbar Affect: Burden of Illness in the USA

Jennifer Colamonico, Andrea E. Formella, Walter G. Bradley · Advances in Therapy · 2012 · 68 citations · Full text

Pharmacy, Health Sciences, Neurology +17

An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions

Gary L. Pattee, James Wymer, Catherine Lomen‐Hoerth et al. · Current Medical Research and Opinion · 2014 · 37 citations · Full text

Medicine, Neurology, Pharmacology +14

PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury

Flora M. Hammond, David N. Alexander, Andrew J. Cutler et al. · BMC Neurology · 2016 · 36 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +17

Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease

Robert A. Hauser, Ryan R. Walsh, Rajesh Pahwa et al. · Frontiers in Neurology · 2021 · 24 citations · Full text

Medicine, Neurology, Pharmacology +17

Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease

Robert A. Hauser, Judy Lytle, Andrea E. Formella et al. · npj Parkinson s Disease · 2022 · 23 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15